भारतीय भेषज संहिता आयोग
स्वास्थ्य एवं परिवार कल्याण मंत्रालय, भारत सरकार
सैक्टर - २३, राज नगर,
गाजियाबाद - २०१ ००२, उत्तर प्रदेश, भारत

सत्यमेव जयते
IPC

INDIAN PHARMACOPOEIA COMMISSION
Ministry of Health & Family Welfare, Government of India
Sector - 23, Raj Nagar
Ghaziabad-201 002 (U.P.), INDIA

डा. वी. कलईशेलवण
सचिव-सह-वैज्ञानिक निदेशक

Dr. V. Kalaiselvan
Secretary-cum-Scientific Director

F. No. T.11015/01/2020-AR&D

Date: June 25, 2026

To,

1. The Drugs Controller General (India)
2. All State Drug Controllers
3. CDSCO Zonal Offices
4. Members of the Scientific Body of the IPC
5. Directors of the Drugs Testing Laboratories
6. IDMA/OPPI/BDMA/FOPE/FSSAI/Small Scale Industry Associations

Subject: Errata 01 to IP 2026

The 10th Edition of Indian Pharmacopoeia (IP) 2026 shall become effective from 1st July, 2026. Based on the scientific inputs, some monographs of the IP 2026 need minor corrections for their effective implementation. Accordingly, Errata 01 to IP 2026 is being issued containing such corrections.

All concerned are requested to bring it to the notice of all authorities under their control for compliance with the IP 2026.

(Dr. V. Kalaiselvan)

Encl. Errata 01 to IP 2026

2.1.7. Balances used in Analytical Procedures. Page 25

Repeatability. Equation 4

Change **from**: $M_{min} = 200 \times s$

to: $M_{min} = 2000 \times s$

2.4.35. Bulk Density of Powders. Page 352

Page 354

Tapped Bulk Density

Change **from**: **Method I – Measurement in a Graduated Cylinder**

to: **Method I – Measurement in a Graduated Cylinder - High Drop**

Fig. 2.4.35-3

Change **to**:



Page 355

Change **from**: **Method II – Measurement in a Volumeter**

to: **Method II – Measurement in a Graduated Cylinder - Low Drop**

Measures of Powder Compressibility. Compressibility Index:

Change **from**:

where, V_0 = untapped bulk,
V_f = final tapped bulk.

to:

where, V_0 = untapped bulk volume,
V_f = final tapped bulk volume.

2.4.50. Chromatographic Separation Techniques. Page 386

Page 386

Dwell Volume (D) (also referred to as V_D). Line 19

Change **from**: (Fig. 2.4.50–1)

to: (Fig. 2.4.50–2)

Page 387

Figure 2.4.50-1

Insert after *h/2*

t_M = hold up time.

Page 388

Relative retention, unadjusted (r_G) ♦or (RRT)♦

Change **from**: $r_C = \frac{t_{Ri}}{t_{Rst}}$

to: $r_G = \frac{t_{Ri}}{t_{Rst}}$

Page 389

Resolution (*Rs*). Equation 1

Change **from**: $R_S = \frac{1.18\,(t_{R2} - t_{R1})}{(w_{h1} - w_{h2})}$

to:

$$R_s = \frac{1.18\,(t_{R2} - t_{R1})}{W_{h1} + W_{h2}}$$

Equation 2

Change **from**: $R_S = \frac{1.18a\,(R_{F2} - R_{F1})}{(w_{h1} - w_{h2})}$

to:

$$R_s = \frac{1.18a\,(R_{F2} - R_{F1})}{W_{h1} + W_{h2}}$$

Retention factor (k)

Change **from**:

$$k' = \frac{\text{amount of component in stationary phase}}{\text{amount of component in mobile phase}} = K_C \times \frac{V_S}{V_M}$$

to:

$$k = \frac{\text{amount of component in stationary phase}}{\text{amount of component in mobile phase}} = K_C \times \frac{V_S}{V_M}$$

Page 391

System repeatability. Equation

Change **from**:

$$per\ cent\ RSD = \frac{100}{y}\sqrt{\frac{\Sigma\ (y_i - \bar{y})}{n-1}}$$

to:

$$per\ cent\ RSD = \frac{100}{\bar{y}}\sqrt{\frac{\Sigma(y_i - \bar{y})^2}{n-1}}$$

Page 392

System repeatability – assay of an active substance or an excipient. After para 2, line 3

Change **from**: $K = \frac{0.6}{\sqrt{2}} \times \frac{t_{90\ per\ cent,\ 5}}{\sqrt{6}}$

to:

where, $K = \frac{0.6}{\sqrt{2}} \times \frac{t_{90\ per\ cent,\ n-1}}{\sqrt{6}}$

Page 395

Table 2 –Example of adjustments for liquid chromatography–gradient elution, line 4

Change **from**: *L/dp12*

to: *L/dp*

Page 395

Column Parameters and flow rate. Line before *Column temperature*

Change **from**: The example below illustrates this process.

to: Table – 2 illustrates the process.

2.5.13. Particle Size Analysis by Dynamic Light Scattering. Page 440

Page 443

Definition of Terms. Average particle diameter, line 3

Change **from**: nanometers.

to: meters.

4.5. Volumetric Reagents and Solutions

Page 1286

Zinc Sulphate, 0.02 M, Line 1

Change **from**: 4.88 g

to: 5.76 g

Parenteral Preparations. Page 1476

Injections. Single-dose containers

Change **to**: **Single-dose containers**. Select 1 container if the nominal volume is 10 ml or more, 3 containers if the nominal volume is more than 3 ml and less than 10 ml, or 5 containers if the nominal volume is 3 ml or less. Take up individually the total contents of each container selected into a dry syringe of a capacity not exceeding 3 times the volume to be measured, and fitted with a 21-gauge needle not less than 2.5 cm in length. Expel any air bubbles from the syringe and needle, then discharge the contents of the syringe without emptying the needle into a standardised dry cylinder (graduated to contain rather than to deliver the designated volumes) of such size that the volume to be measured occupies at least 40 per cent of its graduated volume. Alternatively, the volume of the contents in millilitres may be calculated as the mass in grams divided by the density. For containers with a nominal volume of 2 ml or less, the contents of a sufficient number of containers may be pooled to obtain the volume required for the measurement provided that a separate, dry syringe assembly is used for each container. The contents of containers holding 10 ml or more may be determined by opening them and emptying the contents directly into the graduated cylinder or tared beaker.

The volume is not less than the nominal volume in case of containers examined individually, or, in case of containers with a nominal volume of 2 ml or less, is not less than the sum of the nominal volumes of the containers taken collectively.

Acetylcysteine Injection. Page 1519

Related substances. RRT table

Insert after line 3

Acetylcysteine impurity C[3]	2.2

Insert at the end

[3]3,3'-disulphanediylbis[(2*R*)-2-acetamidopropanoic acid] (*N,N'*-diacetyl-*L*-cystine).

Amlodipine and Olmesartan Medoxomil Tablets. Page 1616

Related substances. After RRT Table, para 4, line 3

Change **from**: Unspecified Amlodipine impurity D

$$= \frac{At_2}{As_2} \times \frac{Cs_2}{Ct_2} \times \frac{Mb_1}{Mb_2} \times 100$$

to: Any unspecified amlodipine related impurity

$$= \frac{At_2}{As_2} \times \frac{Cs_2}{Ct_2} \times \frac{Mb_1}{Mb_2} \times 100$$

Line 8 and 9

Change **from**: Cs_2 = concentration of amlodipine besylate IPRS in reference solution (d) (mg/ml),

to: Cs_2 = concentration of amlodipine besylate IPRS in reference solution (f) (mg/ml),

Barium Sulphate for Suspension. Page 1761

Other tests

Change **from**: Oral Liquids.

to: Oral Powders.

Beclomethasone Dipropionate. Page 1762

Related substances. *Reference solution (a)*, line 2 and 3

Change **from**: 2.8 ml of mobile phase A and dilute to 10.0 ml with mobile phase B.

to: 5.6 ml of mobile phase B and dilute to 10.0 ml with mobile phase A.

Benazepril Hydrochloride Tablets. Page 1770

Assay. Chromatographic system, insert before line 5

- flow rate: 1 ml per minute,

Bendamustine for Injection. Page 1773

Related substances. RRT table, line 10

Change **from**: Bendamustine related compound G^7 -- 1.11

to: Bendamustine related compound G^7 -- 0.90

Benzoic Acid Solution. Page 1788

Insert before **Assay**

Other tests. Comply with the tests stated under Liquids for Cutaneous Application.

Benzhexol Tablets. Page 1784

Insert before **Other tests**

Uniformity of dosage units (2.5.4). Complies with the test stated under Uniformity of dosage units.

Compound Benzoin Tincture. Page 1789

Insert before **Assay**

Other tests. Comply with the tests stated under Liquids for Cutaneous Application.

Betamethasone Valerate. Page 1819

Identification

Insert after **Identification**

Tests A and C may be omitted if tests B and D are carried out. Tests B and D may be omitted if tests A and C are carried out.

C.

Change **to**: C. In the Assay, the principal peak in the chromatogram obtained with the test solution corresponds to the peak in the chromatogram obtained with reference solution (a).

Assay

After chromatographic system, line 7

Change **from**: the reference solution

to: reference solution (a)

Caffeine. Page 1918

Para 2, line 3 and 4

Change **from**: anhydrous basis

to: dried basis

Loss on drying

Insert at the end

, determined on 1.0 g by drying in an oven at 80° for 4 hours.

Calcium Orotate. Page 1932

pH. Insert at the end

(NOTE — Dissolve the substance in boiling water, cool to room temperature before pH determination)

Assay. Line 9

Change **from**: 0.019315 g

to: 0.017515 g

Dibasic Calcium Phosphate, Anhydrous. Page 1933

Fluorides. *Reference solution*, line 1 and 2

Change **from**: Dissolve 0.1105 g of *sodium fluoride IPRS* in *water*.

to: Dissolve 0.1105 g of *sodium fluoride IPRS* in 100.0 ml *water*.

Carboprost Tromethamine Injection. Page 1968

Identification. Last line

Change **from**: carboprost tromethamine.

to: carboprost.

Cefadroxil. Page 1985

Identification

Change **to**: A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with *cefadroxil IPRS* or with the reference spectrum of cefadroxil.

B. Determine by thin-layer chromatography (2.4.17), coating the plate with *silica gel H* and impregnating the dry plate by placing it in a tank containing a shallow layer of about 1 cm of a mixture of 95 volumes of *n-hexane* and 5 volumes of *1-tetradecane*, allowing the solvent to ascend to the top, removing the plate and allowing the solvent to evaporate.

Mobile phase. A mixture of 60 volumes of *0.1 M citric acid*, 40 volumes of *0.1 M disodium hydrogen orthophosphate* and 1.5 volumes of 6.66 per cent w/v solution of *ninhydrin* in *acetone*.

Test solution. A 0.2 per cent w/v solution of the substance under examination in *water*.

Reference solution (a). A 0.2 per cent w/v solution of *cefadroxil IPRS* in *water*.

Reference solution (b). A mixture of equal volumes of the test solution and reference solution (a).

Apply to the plate 20 µl of each solution. After development, dry the plate in air, spray with a 0.2 per cent w/v solution of *ninhydrin* in *ethanol*, dry at 110° for 10 minutes and examine. The principal spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with reference solution (a). The principal spot in the chromatogram obtained with reference solution (b) appears as a single compact spot.

Insert before **Water**

Sulphated ash (2.3.18). Not more than 0.1 per cent.

Cefpodoxime for Oral Suspension. Page 2018

Assay. *Reference solution*

Change **to**: *Reference solution*. A solution of *cefpodoxime proxetil IPRS* containing 0.0025 per cent w/v solution of cefpodoxime in the solvent mixture.

Hard Cellulose Capsule Shells. Page 2045

Disintegration. Insert at the end

(NOTE — This test is not applicable to the capsules intended to use for inhalation preparations).

Arsenic. Change **to**:

Arsenic (2.3.10). Dissolve 3.3 g of capsule shells in 15 ml of *hydrochloric acid* and dilute to 50.0 ml with *carbon dioxide-free water*. The resulting solution complies with the limit test for arsenic (3 ppm) or determined by ICPMS (2.4.42).

Chlordiazepoxide. Page 2072

Related substances. *Reference solution (a)*. Insert at the end

"Dilute 2.0 ml of the solution to 10.0 ml with the mobile phase."

Chlorothiazide Tablets. Page 2091

Assay. Change **to**:

Assay. Determine by liquid chromatography (2.4.14), as described under Related substances with the following modifications.

Test solution. Weigh and powder 20 Tablets. Disperse a quantity of the powder containing 25 mg of Chlorothiazide in 40 ml of the solvent mixture, with the aid of ultrasound and dilute to 50.0 ml with the solvent mixture, centrifuge. Dilute 2.0 ml of the clear supernatant liquid to 10.0 ml with the solvent mixture.

Reference solution. A 0.01 per cent w/v solution of *chlorothiazide IPRS* in the solvent mixture.

Inject the reference solution. The test is not valid unless the tailing factor is not more than 2.0 and the relative standard

deviation for replicate injection is not more than 1.0 per cent.

Inject the reference solution and the test solution.

Calculate the content of $C_7H_6ClN_3O_4S_2$ in the tablets.

Chloroxylenol. Page 2092

Assay. Change **to**:

Assay. Weigh accurately about 70 mg, dissolve in 30 ml of *glacial acetic acid*, add 25.0 ml of *0.0167 M potassium bromate*, 20 ml of 15 per cent w/v solution of *potassium bromide* and 10 ml of *hydrochloric acid*, stopper the flask and allow to stand protected from light for 15 minutes. Add 1 g of *potassium iodide* and 100 ml of *water* and titrate with *0.1 M sodium thiosulphate*, shaking vigorously and using 1 ml of *starch solution* as indicator. Repeat the procedure without the substance under examination. The difference between the titrations represents the amount of potassium bromate required.

1 ml of *0.0167 M potassium bromate* is equivalent to 0.003915 g of C_8H_9ClO.

Chlorpheniramine Maleate. Page 2093

Related substances. After chromatographic system, para 1, line 5

Change **from**: chlorpheniramine

to: pheniramine

Cinnarizine. Page 2120

Related substances. *Reference solution (b)*

Insert at the end

Dilute 5.0 ml of the solution to 20.0 ml with *methanol*.

Cisplatin Injection. Page 2133

Para 1

Change **from**: Cisplatin Injection is a sterile solution of Cisplatin in water for injections. It is either supplied as a ready-to-use solution or it is prepared by dissolving Cisplatin for Injection in the requisite amount of water for injections immediately before use.

to: Cisplatin Injection is a sterile solution of Cisplatin in water for injections.

Para 2

Change **from**: *The injection complies with the requirements stated under Parenteral Preparations.*

to: *The injection complies with the requirements stated under Parenteral Preparations (Injections).*

Para 3

Delete the requirement.

Clobetasol Propionate. Page 2167

Specific optical rotation

Insert at the end

"at 20°".

Related substances. *Reference solution (c)*, line 1 and 2

Change **from**: Dissolve the contents of a vial of *clobetasol impurity J IPRS*

to: Dissolve 0.4 mg of *clobetasol impurity J IPRS*

Cloxacillin for Oral Solution. Page 2198

Insert before **Assay**

Other tests. Comply with the tests stated under Oral Powders.

Cyproheptadine Hydrochloride. Page 2254

Para 2

Delete the following requirement.

"Cyproheptadine Hydrochloride contains not less than 98.5 per cent and not more than 101.0 per cent of $C_{21}H_{21}N,HCl$, calculated on anhydrous basis."

Related substances. *Reference solution (a)*, line 1

Change **from**: 0.002 per cent

to: 0.0002 per cent

Dapagliflozin Propanediol Monohydrate. Page 2287

Water. Line 2

Change **from**: 0.1 g.

to: 0.5 g.

Dasatinib. Page 2303

Related Substances. After RRT table, IUPAC names

Change **to**:

[1]2-amino-*N*-(2-chloro-6-methylphenyl)-thiozole-5-carbomide,

[2]*N*-(2-chloro-6-methylphenyl)-2-[[6-chloro-2-methyl-4-pyrimidinyl] amino]-5-thiazolecarboxamide.

Dicloxacillin for Oral Suspension. Page 2377

Other tests

Change **from**: Oral Liquids.

to: Oral Powders.

Dipivefrine Hydrochloride. Page 2420

Assay. Insert after para 1

Test solution. Dissolve 50 mg of the substance under examination in the solvent mixture and dilute to 5.0 ml with the solvent mixture. Dilute 1.0 ml of the solution to 100.0 ml with the solvent mixture.

Docetaxel Anhydrous. Page 2440

Specific optical rotation. Insert at the end

"at 20°".

Docetaxel Trihydrate. Page 2441

Specific optical rotation. Insert at the end

"at 20°".

Dutasteride. Page 2491

Water. Insert at the end

, using Method 3.

Eribulin Injection. Page 2557

Related substances. After chromatographic system, para 2, line 21 and 22

Change **from**: and the sum of the areas of all secondary peaks other than eribulin impurity E is not more than

to: and the sum of the areas of all the secondary peaks is not more than

Ethylcellulose. Page 2600

Chlorides. Insert at the end

using 10 ml of *chloride standard solution (5 ppm Cl)*.

Fentanyl Injection. Page 2654

Related substances. *Reference solution (a)*, line 1

Change **from**: 0.125 per cent

to: 0.0000125 per cent

Ferric Carboxymaltose. Page 2655

Zeta potential. Line 1

Change from: Limit not less than +3.0.

to: Limit not less than +3.0 (mV).

Fexofenadine Hydrochloride. Page 2663

Chlorides. Line 1

Insert at the end

, calculated on anhydrous basis.

Finasteride. Page 2671

Related substances. After RRT table, line 2

Change **from**: carboxamide (Δ-1,5-aza amide),

to: (dihydrofinasteride),

Line 4

Change **from**: (dihydrofinasteride).

to: carboxamide (Δ5-finasteride).

Flucloxacillin for Oral Solution. Page 2679

Other tests

Change **from**: Oral Liquids.

to: Oral Powders.

Fluconazole for Oral Suspension. Page 2682

Other tests before **Assay**

Delete the requirement

Fluocinolone Acetonide. Page 2698

Related substances. *Reference solution (a)*, line 1 and 2

Change **from**: *fluocinolone acetonide IPRS*

to: the substance under examination

Frusemide. Page 2752

Assay. After chromatographic system, para 1, line 3

Change **from**: 2.5

to: 1.5

Fulvestrant. Page 2756

Enantiomeric purity. Line 1 and 2

Change **from**: Fulvestrant epimer B is 52.0 to 58.0 per cent and Fulvestrant epimer A is 42.0 to 48.0 per cent.

to: Fulvestrant epimer B is 52 to 58 per cent and Fulvestrant epimer A is 42 to 48 per cent.

Gelatin. Page 2779

Peroxides. Lines 3 to 7

Change **from**: Remove the test strip, shake off excess liquid and compare the reaction zone after 15 seconds with the colour scale provided with the test strips used. The colour must match that of the 10 ppm concentration, otherwise the test is invalid.

to: Remove the test strip, shake off excess liquid and after 15 seconds, compare the reaction zone with the colour scale provided. The test strips are suitable if the colour matches that of the 2 ppm concentration.

Glipizide. 2805

B. Limit of Glipizide related compounds A, B and C.

After Chromatographic system, line 13 and 14

Change **from**: glipizide related compounds A, B and C peaks

to: glipizide related compound A and B peaks

Assay. Line 15 and 16

Change **from**: glipizide related compounds A, B and C peaks

to: glipizide related compound A and B peaks

Hydrochlorothiazide. Page 2858

Assay. *Test solution*, line 1

Change **from**: *Test solution.*

to: *Test solution (a).*

Reference solution, line 1

Change **from**: *Reference solution.*

to: *Reference solution (c).*

After impurity table, line 1

Change **from**: the reference solution

to: reference solution (a)

Line 4

Change **from**: Inject the reference solution and the test solution.

to: Inject reference solution (c) and test solution (a).

Hydrocortisone Sodium Succinate for Injection. Page 2869

Related substances. *Reference solution (b)*

Change **to**: *Reference solution (b)*. A 0.035 per cent w/v solution of *hydrocortisone IPRS* in *acetonitrile*. Dilute 5.0 ml of the solution to 10.0 ml with *water*.

Hydroxyethyl Cellulose. Page 2877

Nitrates. Para 1, line 2 and 5

Change **from**: 100 mPa.s

to: 1000 mPa.s

Hydroxyzine Oral Solution. Page 2890

Related substances. *Reference solution (b)*, line 1

Change **from**: 1.0 ml

to: 2.0 ml

Reference solution (c). Insert at the end

Dilute 5.0 ml of the solution to 10.0 ml with the mobile phase.

Hyoscine Butylbromide. Page 2892

Related substances. *Reference solution (a)*, line 2

Change **from**: the mobile phase.

to: mobile phase B.

Hyoscyamine for Oral Solution. Page 2901

Para before **Identification**, line 2

Change **from**: *Oral liquids*

to: *Oral powders*

Isopropyl Alcohol. Page 2979

Benzene and related substances. Insert after chromatographic system, para 1

Inject reference solution (a). The test is not valid unless the resolution between the peak due to 1-propanol and 2-butanol is not less than 10.

Melphalan Tablets. Page 3222

Assay. After chromatographic system, para 2 and 3

Change **to**: Calculate the content of $C_{13}H_{18}Cl_2N_2O_2$ in the tablets.

Meropenem for Injection. Page 3240

Insert before **Bacterial endotoxins**

Content of Sodium. 80 per cent to 120 per cent of the labelled amount of sodium.

Weigh a quantity of the injection containing 50 mg of anhydrous meropenem and dissolve in sufficient *water* to produce 100.0 ml. Dilute the resulting solution appropriately with *water* and determine by Method A for flame photometry (2.4.4), measuring at 589 nm or by Method A for atomic absorption spectrophotometry (2.4.2), using *sodium solution FP* or *sodium solution AAS* respectively, suitably diluted with *water* for the reference solutions.

Microcrystalline Cellulose. Page 3323

Bulk density. Line 1

Change **from** : **Bulk density**

to: **Bulk density of powders**

Minocycline Hydrochloride. Page 3334

Related substances. *Buffer solution*, line 2

Change **from**: 0.28 per cent

to: 2.8 per cent

Minocycline Capsules. Page 3336

Related substances. *Buffer solution*, line 2

Change **from**: 0.28 per cent

to: 2.8 per cent

Minocycline Tablets. Page 3338

Related substances. *Buffer solution*, line 2

Change **from**: 0.28 per cent

to: 2.8 per cent

Montelukast Sodium. Page 3358

Related substances. After RRT table, para 2, line 2

Change **from**: montelukast impurity B

to: montelukast impurity G

Naloxone Hydrochloride. Page 3426

Related substances. Chromatographic system, mobile phase A, line 2

Change **from**: 40 volumes of *tetrahydrofuran*

to: 4 volumes of *tetrahydrofuran*

Neotame. Page 3453

Related substances. Last para, lines 2 to 6

Change **from**: In the chromatogram obtained with the test solution, the area of peak corresponding to neotame impurity

A is not more than 1.5 times the area of the principal peak in the chromatogram obtained with reference solution (b) (1.5 per cent)

to: In the chromatogram obtained with the test solution, the area of peak corresponding to neotame impurity A is not more than the area of the principal peak in the chromatogram obtained with reference solution (b) (1.5 per cent)

Nifedipine. Page 3471

Related substances. After chromatographic system, para 2, lines 1 to 3

Change **from**: The test is not valid unless the resolution between the peaks due to the nitrosophenylpyridine analogue and nifedipine is not less than 1.5,

to: The test is not valid unless the resolution between the peaks due to the nitrophenylpyridine analogue and nitrosophenylpyridine analogue is not less than 1.5,

Nitroglycerin Injection. Page 3487

Change **from**: Nitroglycerin Injection is a sterile solution of Diluted Nitro4 colourless solution.

to: Nitroglycerin Injection is a sterile solution of Diluted Nitroglycerin, which may contains alcohol and propylene glycol in Water for Injections.

Nitroglycerin Injection contains not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of nitroglycerin ($C_3H_5N_3O_9$).

Description. A clear colourless solution.

Omeprazole Gastro-resistant Capsules. Page 3532

Dissolution. A

Test solution: Last line

Change **from**: mobile phase.

to: solvent mixture.

Reference solution: Last line

Change **from**: mobile phase.

to: solvent mixture.

Paracetamol. Page 3616

Related substances. *Reference solution (a)*, line 1

Change **from**: 0.0002 per cent

to: 0.002 per cent

Poloxamers. Page 3744

Ethylene oxide, propylene oxide and dioxan. *Ethylene oxide stock solution*

Change **to**: *Ethylene oxide stock solution*. A 5 per cent w/v solution of *ethylene oxide* in *dichloromethane*. Dilute 0.5 ml of the solution to 50.0 ml with *dimethyl sulphoxide*.

After chromatographic system, para 1, line 1

Change **from**: 1 µl

to: 1 ml

Rosuvastatin Tablets. Page 4000

Related substances. *Reference solution (c)*, line 1

Change **from**: 0.0001 per cent

to: 0.1 per cent

Salbutamol Tablets. Page 4026

Related substances. Chromatographic system, line 2

Change **from**: (3 µm)

to: (5 µm)

Sodium Carbonate. Page 4075

Insert before **Appearance of solution**

Solution A. Dissolve 2.0 g in a mixture of 5 ml of *hydrochloric acid* and 25 ml of *water*. Heat the solution to boiling and cool. Add *dilute sodium hydroxide solution* until the solution is neutral and dilute to 50 ml with *water*.

Stavudine for Oral Solution. Page 4140

Para before **Identification**, line 2

Change **from**: *Oral Liquids*

to: *Oral powders*

Tenofovir Disoproxil Fumarate Tablets. Page 4233

Related substances. *Reference solution (a)*, line 3

Change **from**: the solvent mixture.

to: mobile phase A.

Tranexamic Acid. Page 4343

Related substances. Last para, line 15 and 16

Change **form**: the area of the principal peak in the chromatogram obtained with reference solution (a) (0.05 per cent)

to: the area of any other secondary peak is not more than 0.1 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.05 per cent)

Ursodeoxycholic Acid. Page 4400

Identification. B, line 1 and 3

Change **from**: spot

to: peak

Vancomycin for Intravenous Infusion. Page 4426

Related substances and vancomycin B. After Chromatographic system, para 3 line 1

Change **from**: Inject the test solution.

to: Inject the test solution and reference solution (c). In the chromatogram obtained with the test solution, integrate all peaks present with an area more than the area of the principal peak in the chromatogram obtained with reference solution (c) to determine the total peak area.

Vildagliptin and Metformin Prolonged-release Tablets. Page 4451

Para 2, line 1

Change **from**: capsules

to: tablets

Related substances

For Metformin Hydrochloride —

Reference solution (b), line 2

Insert at the end

Dilute 1.0 ml of the solution to 10.0 ml with the solvent mixture.

Xanthan Gum. Page 4487

Viscosity. Line 12

Change **from**: diameter and .6 mm high

to: diameter and 1.6 mm high

BIOTECHNOLOGY DERIVED THERAPEUTIC PRODUCTS

Trastuzumab Concentrated Solution. Page 5204

Para 1 and 2

Change **to**: Trastuzumab Heavy Chain Chimeric

EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRY
ADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS
GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGG
PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN
STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREE
MTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW
QQGNVFSCSVMHEALHNHYTQKSLSLSPGK

Trastuzumab Light Chain Chimeric

DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPS
RFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIKRTVAAPSVFIFPP
SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT
LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

VETERINARY PRODUCTS

Ampicillin Injection. Page 5355

Title Change **to**: **Ampicillin for Injection**